SurpassMD review
The figure depends on eligibility, medication, dose and provider approval, all stated.
The verdict
SurpassMD publishes semaglutide as low as $114 a month and tirzepatide at $177, for eligible patients. The site states actual pricing depends on medication, dose and provider approval. Coverage is 51 jurisdictions.
Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.
- Category
- GLP-1 telehealth
- Molecule
- Semaglutide · Tirzepatide
- Form
- Injection
- States
- 51
- From
- From $114/mo
- Prescription
- Required
- Compounded
- Yes — not FDA-approved
- Availability
- 51 jurisdictions
SurpassMD sells both molecules by injection across 51 jurisdictions. Both figures carry stated conditions. Neither is a settled rate.
Who writes the prescription, and what do they see?
Provider approval is named as one of the three things that moves the price. That makes the clinician part of the pricing, which the site says outright.
Four conditions sit on one number: eligibility, medication, dose and approval. Listing them is honest. It also means the figure describes very little on its own.
What happens when the dose goes up?
Dose is named as a variable that changes the price. What it changes it to is not published. Direction without a destination is half an answer.
What the price includes
Six months at $114 is $684 at best. Tirzepatide at $177 is $1,062 at best. Both totals assume every condition resolves favorably. Ask what your own figure is before ordering.
What it claims, and what it cites
Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.
Where it holds up, and where it does not
- Strength: The conditions are listed, not hidden
- Strength: Coverage across 51 jurisdictions
- Strength: Both molecules carry a figure
- Limitation: Eligibility gates the published rate
- Limitation: Dose changes it by an unstated amount
- Limitation: Provider approval also moves it
- Limitation: The pharmacy behind the vial is unnamed
What the evidence says about this kind of treatment
The assessment above is about SurpassMD. These are about the drugs it sells, and they are traced to the primary literature.
- Right for
- A reader who will ask what their own approved figure is.
- Wrong for
- A reader planning six months from the published rate.
The evidence behind what SurpassMD prescribes
These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.
- Cochrane Review of Semaglutide for Obesity: 18 Trials Graded
A 2025 Cochrane review pooled eighteen randomized trials. The weight figure is high certainty and smaller than the marketing, and almost everything else is graded lower.
- Tirzepatide vs Semaglutide: Which Works Better for Weight Loss?
In a 72-week randomized trial at weight-management doses, weight fell 20.2 percent on tirzepatide and 13.7 percent on semaglutide. Routine-care studies found a smaller gap, three to four points.
How SurpassMD compares
| Seller | Who it suits | Go |
|---|---|---|
 Somira Health | Readers who want the pharmacy and the rate named before the intake | See Somira Health → |
 Sunlight | Readers who want a rate guaranteed against increases and will count the fills | See Sunlight → |
 TeleCareSpot | Readers confident of approval who want a flat all-in rate | See TeleCareSpot → |
More GLP-1 telehealth sellers reviews: NurxOlleve CareOmada HealthOne80RxPillar HealthPrescriva
Sponsored alternative
SkinnyRx
Readers choosing tirzepatide, the one line with a published standing rate
Check SkinnyRx availability →Frequently asked
- Will I pay $114?
- Only if eligible, and the site states pricing also depends on medication, dose and provider approval.
- Does the price rise with the dose?
- Dose is named as a factor. What it raises the figure to is not published.
- Where does SurpassMD ship?
- Fifty-one jurisdictions are recorded.
- Is SurpassMD legit?
- SurpassMD is a GLP-1 telehealth sellers service. Its stated availability: 51 jurisdictions. What our record does not establish: whether it bills insurance and how its intake works. Ask for those in writing before you pay.
- Is SurpassMD expensive compared with other GLP-1 telehealth sellers?
- SurpassMD publishes a starting figure of $114/mo. Across the 402 GLP-1 telehealth sellers we review that publish a single monthly figure, those run $49 to $525.42 with a median of $190, which puts SurpassMD below the median, toward the cheaper end. The other 178 GLP-1 telehealth sellers we review quote only after an intake or price by dose, so they are not in that comparison. A starting figure is not a bill — labs, consultations and shipping are often charged separately, so confirm what your own quote includes.